The board of directors of Sihuan Pharmaceutical Holdings Group Ltd. announced that Ticagrelor Orodispersible Tablet (Strength: 90 mg)(the ?Product?), developed by the Group's subsidiary Honghe Pharmaceutical Co. Ltd. has obtained drug registration approval from the National Medical Products Administration of the People's Republic of China. It is deemed as passing the consistency evaluation on quality and efficacy of generic drugs.

The Product developed by Honghe Pharmaceutical is the first domestic product to be approved for launch. Ticagrelor is a novel antithrombotic drug with strong antiplatelet aggregation to prevent thrombosis. It has been recommended by Chinese and international guidelines as an antiplatelet agent for thrombosis prevention in patients with cardiovascular disease.

Ticagrelor Orodispersible Tablet is classified as Class B drug under the National Reimbursement Drug List (NRDL). According to public data, the Farber Core Hospital Market Data shows that the market size of oral anticoagulant drugs in core hospitals in China exceeded RMB 10 billion in 2023. The cardiovascular and cerebrovascular field is a key deployment field of Group.

The approval of Ticagrelor Orodispersible Tablet will further benefit patients and add another significant variety to the Group's cardiovascular and cerebrovascular drug pipeline, and will have a positive impact on the operating performance of the Group.